iSpecimen Inc. received a Nasdaq Deficiency Letter on September 8, 2026, for failing to maintain minimum stockholders' equity under Listing Rule 5550(b). Nasdaq granted an extension until November 25, 2026, to regain compliance. The company cites a private placement closing May 11, 2026, which generated approximately $2.5 million in gross proceeds, and plans for a best-efforts public offering of approximately $5 million. Financial projections indicate stockholders' equity of roughly $5.1 million through June 30, 2027. Failure to evidence compliance by the deadline or in the next periodic report may result in delisting from the Nasdaq Capital Market. iSpecimen Inc. operates in the healthcare technology industry, providing digital pathology solutions.

iSpecimen Inc. entered into an Asset Purchase Agreement with Foldlab AI Ltd. to acquire specific artificial intelligence software, models, source code, and data rights, including the Disease-Associated Protein Discovery AI Agent. The aggregate purchase price is $4,500,000, consisting of $2,000,000 in cash and $2,500,000 in common stock. Cash consideration includes an initial $750,000 payment at closing plus two milestone payments of $625,000 each, payable only upon successful delivery and acceptance of the AI products. The stock portion is issued based on a ten-day volume-weighted average price prior to closing and is subject to a five-year escrow with no leak-out. Closing is contingent on customary conditions, including stockholder approval and Nasdaq listing confirmation. iSpecimen Inc. operates in the biotechnology industry, providing AI-driven solutions for drug discovery and disease research.

iSpecimen Inc. entered into a consulting agreement with IR Agency LLC on August 12, 2026, for marketing and advertising services including company profile creation and media distribution. The three-month term allows for up to ten news releases, with an aggregate cash fee of $2,000,000 payable by August 13, 2026. This fee is fully earned upon receipt and non-refundable, regardless of whether the company terminates the agreement early or if services are suspended due to risk concerns. The company operates in the healthcare technology sector, providing digital pathology solutions.

iSpecimen Inc. entered into a Settlement Agreement with WestPark Capital to resolve an arbitration dispute regarding investment banking services for the company's July 2025 public offering, which raised approximately $4.0 million in gross proceeds. WestPark had sought damages of $269,999.91 plus interest and fees; the Company paid $97,500 to settle all claims without admitting liability. The Engagement Agreements were terminated entirely, including any tail fees or rights of first refusal, with each party bearing its own costs. The settlement payment is expected to be recorded as a charge in the quarter ending September 30, 2026. iSpecimen Inc. operates in the biotechnology industry, providing specimen collection and logistics services.

iSpecimen Inc. closed a public offering on August 7, 2026, raising approximately $5 million by selling 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 additional shares at a price of $1.30 per share. The company paid E.F. Hutton & Co. a 4% placement fee plus expenses. Proceeds will be used for debt repayment, potential acquisitions, marketing, and working capital. iSpecimen operates an online marketplace connecting scientists with healthcare providers to source biospecimens for medical research.

On July 9, 2026, iSpecimen Inc. completed Milestone 3 of its digital transformation program powered by SalesStack Solutions. In accordance with the Definitive Software Purchase and Services Agreement, the company made a payment of $700,000 upon completion. This milestone adds marketplace features, expands geographic rollout, and increases partner ecosystem integrations. iSpecimen operates in the biotechnology industry, providing biospecimen procurement and management services.